GLR in Colorectal Cancers: An Easily Accessible Prognostic Marker
İsa Aydin,Ismail Subasi,Ahmet Sunar,Serkan Ademoglu,Selcuk Gulmez,Mursit Dincer,Mustafa Duman,Erdal Polat
DOI: https://doi.org/10.2147/ijgm.s463769
IF: 2.145
2024-05-23
International Journal of General Medicine
Abstract:&Idotsa Caner Aydin, 1 Ismail Ege Subasi, 2 Ahmet Orhan Sunar, 1 Serkan Ademoglu, 1 Selcuk Gulmez, 1 Mursit Dincer, 1 Mustafa Duman, 1 Erdal Polat 1 1 University of Health Sciences, Kartal Kosuyolu Training and Research Hospital, Gastroenterologic Surgery Department, Istanbul, Turkey; 2 University of Health Sciences, Van City Hospital Gastroenterologic Surgery Department, Van, Turkey Correspondence: &Idotsa Caner Aydin, University of Health Sciences, Kartal Kosuyolu Training and Research Hospital, Gastroenterologic Surgery Department, Email Background and Objectives: Colorectal cancer remains a significant health concern, necessitating reliable prognostic indicators for effective management. This study explores the preoperative prognostic significance of the Glucose/Lymphocyte Ratio (GLR) in colorectal cancers. Methods: The study retrospectively analyzed records of patients who underwent surgery for elective colorectal cancers between January 1, 2013, and December 31, 2021, at the Ko&scediluyolu Training and Research Hospital Gastroenterologic Surgery Department. Demographic, clinicopathological, and follow-up data were comprehensively assessed. A cutoff was established from GLR ratios and patients were divided into two groups for prognosis analysis. Results: The study enrolled 222 eligible patients, examining variables such as age, sex, ASA score, neoadjuvant treatment, lymphovascular and perineural invasion, tumor grade, TNM stage, and GLR. The groups consisted of 128 patients with low GLR and 94 patients with high GLR. Statistical analyses revealed relations between GLR levels (p ≤ 0.001) and various prognostic factors such as age (p = 0.034), Perineural Invasion (PNI) (p = 0.002), tumor grade (p = 0.017), TNM stage (p = 0.003), and surgery time (p = 0.029), individuals with GLR ≥ 3.04 were observed to show higher mortality rates (p = 0.001). Above GLR cutoff point of 3.04 patients showed better overall survival rates. All survival related parameters were related with prognosis in univariant Cox regression tests. In multivariant cox regression tests GLR ≥ 3.04 significantly increased mortality by 2.9 times. (p = 0.003). Conclusion: This study demonstrates that GLR, calculated from preoperative glucose and lymphocyte values serves as an independent prognostic factor in colorectal cancers. The findings suggest potential applications for GLR in survival analyses, with significant associations identified in age, PNI, tumor grade, TNM stage, and surgery time. Further investigations are warranted in homogeneous patient populations. Keywords: colorectal cancer, prognostic factor, survival, Glucose-to-lymphocyte Ratio, cancer-specific survival Colorectal cancers rank as the fourth most prevalent cancer globally, yet advancements in screening methods and surgical techniques enable early diagnosis. 1 Not only screening methods but also clinical presentations such as colorectal cancer of unidentified origin (CUP) contribute to the increased incidence of colorectal cancers, despite being considered as favorable variants of colorectal cancer in these clinical contexts. 2 Postoperative follow-up protocols primarily rely on patients' pathological results, with an increasing tendency toward the use of serum biomarkers in contemporary practices. CEA and CA19.9 values, commonly used in post-diagnosis recurrence monitoring, can also be utilized for diagnosis, unlike in the metastatic disease presence where they are found to be high together with K-Ras mutation. Tissue K-ras activity is used in assessing tumor aggressiveness and chemotherapy sensitivity, while miRNAs are markers that can be found in tissue or blood, showing a spectrum of effects whose diversity is still under research. The miR-19a oncogene associated with FOLFOX resistance in advanced stage CRCs, while upregulation of miR-126 is correlated with bevacizumab resistance in terms of treatment response to anti-VEGF or anti-EGFR inhibitors effective in metastatic colon cancers; conversely, overexpression of miR-31, miR-100, miR-125b, and downregulation of miR-7 are respectively associated with cetuximab resistance. 3 Easily accessible prognostic markers are not only significant in cancer patients but also hold importance in various clinical aspects. Studies have indicated the potential utility of easily accessible tests such as Neutrophil/Lymphocyte Ratio (NLR), Platelet/Lymphocyte Ratio (PLR), Lymphocyte/Monocyte Ratio (LMR), and the "Hematocrite, Albumin, Leukocyte, and Platelet" (HALP) score in assessing the prognosis of colon cancers. 4–8 The prognostic value of a novel marker, the preoperative Glucose/Lymphocyte Ratio (GLR -Abstract Truncated-
medicine, general & internal